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Systematic review
Meta-analysis of prognostic factors for patients with colorectal
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and heated intraperitoneal chemotherapy
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Background: Up to 15 per cent of colorectal cancers present with peritoneal metastases (CPM). Cyto-
reductive surgery and heated intraperitoneal chemotherapy (CRS+HIPEC) aims to achieve macroscopic
tumour resection combined with HIPEC to destroy microscopic disease. CRS+HIPEC is a major
operation with significant morbidity and effects on quality of life (QoL). Improving patient selection
is crucial to maximize patient outcomes while minimizing morbidity and mortality. The aim of this study
was to identify prognostic factors for patients with CPM undergoing CRS+HIPEC.
Methods: A systematic search of MEDLINE, Embase and Cochrane Library electronic databases was
performed using terms for colorectal cancer, peritoneal metastasis and CRS+HIPEC. Included studies
focused on the impact of prognostic factors on overall survival following CRS+HIPEC in patients
with CPM.
Results: Twenty-four studies described 3128 patients. Obstruction or perforation of the primary tumour
(hazard ratio (HR) 2⋅91, 95 per cent c.i. 1⋅5 to 5⋅65), extent of peritoneal metastasis as described by the
Peritoneal Carcinomatosis Index (PCI) (per increase of 1 PCI point: HR 1⋅07, 1⋅02 to 1⋅12) and the
completeness of cytoreduction (CC score above zero: HR 1⋅75, 1⋅18 to 2⋅59) were associated with reduced
overall survival after CRS+HIPEC.
Conclusion: Primary tumour obstruction or perforation, PCI score and CC score are valuable prognostic
factors in the selection of patients with CPM for CRS+HIPEC.
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Introduction
Colorectal peritoneal metastasis (CPM) occurs in up to 15
per cent of patients with colorectal cancer1–3. The progno-
sis of patients with CPM is poor: untreated median overall
survival (OS) is just 6 months4. With systemic chemother-
apy, median OS is improved to up to 20 months5–7. The
standard for CPM is cytoreductive surgery and heated
intraperitoneal chemotherapy (CRS+HIPEC), whichmay
improve median OS by 20–63 months8–16.
CRS+HIPEC is a long, high-cost operation associ-
ated with a protracted inpatient and high-dependency
or intensive care unit stay, and an associated mortality
rate of 1–12 per cent and morbidity rate of 7–63 per
cent11,14,16–23. Improving patient selection is therefore
crucial to maximize patient outcomes whilst minimizing
morbidity and mortality.
Variation in outcomes for CRS+HIPEC can be
explained in part by patient selection, for example neces-
sitating the ability to achieve complete cytoreduction at
CRS, the exclusion of patients with extensive CPM as
assessed by Sugarbaker’s Peritoneal Carcinomatosis Index
(PCI), and selection of patients with minimal co-morbidity
and good performance status.
Several clinicopathological variables that impact on
survival have been identified in the literature, includ-
ing lymph node (LN) status, tumour differentiation and
histological findings, the completeness of cytoreduction
(CC score) and PCI. There is wide variation, however, in
the variables reported by studies and selection criteria for
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centres performing CRS+HIPEC worldwide, and in turn
in their outcomes.
Studies reporting prognostic factors for CRS+HIPEC
are cohort in design with small samples, and each examines
numerous and varying prognostic factors on differing scales
of measurement. No consensus exists as to which prognos-
tic factors contraindicate CRS+HIPEC, or predict a good
outcome. A comprehensive evidence synthesis is therefore
called for to determine relevant prognostic factors.
The aim of this systematic review and meta-analysis was
to analyse all prognostic factors affecting OS in patients
with CPM undergoing CRS+HIPEC.
Methods
A comprehensive literature search was conducted
in accordance with the PRISMA guidelines24. MEDLINE,
Embase and Cochrane Library electronic databases, reg-
isters of clinical trials (ClinicalTrials.gov and the WHO
International Clinical Trials Registry) and the Conference
Proceedings Citation Index, Zetoc, were searched from
inception to the present. The search strategy captured
terms for colorectal cancer, peritoneal metastasis and
CRS+HIPEC techniques, separated by the Boolean
operator ‘AND’. For an example search strategy, see
Appendix S1 (supporting information). Searches were sup-
plemented by a hand search of selected journals and the
reference lists of all included studies.
Study selection
English-language articles were eligible for inclusion if
they reported on the impact of prognostic factors on OS
in patients with CPM undergoing CRS+HIPEC. Where
multiple studies described the same cohort of patients,
the largest and most complete data set was included.
Review articles, case reports and case series of fewer
than ten patients were excluded. Additional exclusion cri-
teria included studies involving patients with a primary
tumour other than colorectal cancer and studies in which
a proportion of the cohort did not receive combined
CRS+HIPEC.
After screening the titles and abstracts, articles ful-
filling the eligibility criteria were identified and their
full-text publications reviewed. Literature search and study
selection were done independently by two researchers,
and any disagreements were resolved by discussion with
senior reviewers. After qualitative assessment, articles were
screened to ensure they presented adequate statistical
information to be included in the meta-analysis: hazard
ratios (HRs) with confidence intervals or Kaplan–Meier
curves with the number of events and patients at risk.When
HRs, confidence intervals or P values were not provided
directly, the methods of Tierney et al.25 were used to esti-
mate them indirectly from Kaplan–Meier curves, when
presented in adequate detail with the numbers of events and
patients at risk26.
Assessment of risk of bias
The quality and risk of bias of individual studies was
assessed using the Quality in Prognosis Studies (QUIPS)
tool27. This tool reviews each study according to six
criteria: study participation, attrition, prognostic factor
measurement, outcome measurement, confounding fac-
tors, and statistical analysis and reporting. Two authors
scored all articles independently.
Data extraction
Data were extracted independently by two reviewers using
a dedicated and piloted data extraction form. The number
of patients, study design, patient demographics, tumour
characteristics, use of adjuvant and neoadjuvant regimens,
CRS+HIPEC techniques, survival and prognostic factors
were recorded.
The unadjusted HR and its 95 per cent c.i. and P
value were extracted.When adjustedHRs (with confidence
intervals and P values) were reported, these were extracted
along with the set of adjustment factors used. If HRs, con-
fidence intervals or P values were not provided directly,
the methods of Tierney and colleagues25 were used to esti-
mate them indirectly from Kaplan–Meier curves, when
presented in adequate detail with the numbers of events and
patients at risk26.
Prognostic factors reported on a continuous scale were
extracted. If results were categorized into three or more
categories, results for each comparison were extracted and,
when clinically relevant, were grouped to form a binary
comparison.
Prognostic factor selection
All prognostic factors described adequately and reported
by two or more independent studies were included.
Statistical analysis
Owing to clinical and methodological heterogeneity, a
random-effects meta-analysis was used (on the log(HR)
scale) using the method of DerSimonian and Laird28. The
combined effect size was described by the pooled HR, its
confidence interval and P value, with P< 0⋅050 considered
significant. For prognostic factors reported by more than
© 2019 The Authors. www.bjsopen.com BJS Open
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
Prognostic factors in colorectal peritoneal metastasis
Fig. 1 PRISMA diagram for the review
Records screened after duplicates removed
n= 1052
Id
en
tif
ic
at
io
n
S
cr
ee
ni
ng
E
lig
ib
ili
ty
In
cl
ud
ed
Full-text articles assessed for eligibility
n= 158
Studies included in qualitative synthesis n= 51
 Paper looked only at prognostic factors n= 4
 Conference abstract presenting inadequate data n= 11
 Paper presenting inadequate statistical data n= 12
Studies included in
quantitative synthesis
(meta-analysis)
n= 24
Records excluded after screening of title and abstract n= 894
 Incorrect topic n= 391
 Narrative review n= 186
 Foreign language n= 106
 Additional duplicates removed manually n= 76
 Incorrect primary tumour type (none colorectal) n= 33
 Mixed primary tumour types with no subgroup analysis for
 colorectal n= 42
 No analysis of prognostic factors n= 22
 Systematic reviews and meta-analyses n= 17
 No peritoneal metastasis (preventive adjuvant HIPEC) n= 7
 Case reports, case series <10 n = 9
 Consensus statements n= 4
 No HIPEC given n= 1
Records excluded after full-text review n= 107
 Duplicate data (data presented from same time period and institution
 or conference abstract later published as full paper) n= 32
 Mixed primary tumour n= 27
 No analysis of prognostic factors n= 20
 CRS+HIPEC not given to all patients n= 15
 Incorrect outcome measure (PFS/DFS) n= 10
 Repeat procedure for recurrence after CRS+HIPEC n= 2
 Foreign language n= 1
Records identified through database searching of Ovid MEDLINE, Embase, Cochrane (CENTRAL, CDSR), 
registers of clinical trials (ClinicalTrials.gov and WHO International Clinical Trials Registry)
and the Conference Proceedings Citation Index, Zetoc, and reference search of identified articles
n= 1544
CENTRAL, Cochrane Central Register of Controlled Trials; CDSR, Cochrane Database of Systematic Reviews; DARE, Database of Abstracts of Reviews
of Effects; HIPEC, heated intraperitoneal chemotherapy; CRS, cytoreductive surgery; PFS, progression-free survival; DFS, disease-free survival.
two studies, a 95 per cent prediction interval (a measure of
the variation in treatment effects) is presented29. Hetero-
geneity was also described by the I2 statistic30. All analyses
were performed in STATA® version 15 (StataCorp, Col-
lege Station, Texas, USA).
Results
The final literature search was performed on 3 April
2018. Literature searches (after removal of duplicates)
identified 1052 records. Titles and abstract screening
identified 158 full-text articles for review. Of these,
51 studies met the inclusion criteria. Twenty-four
unique studies11,18,20,31–51 reporting on 3128 patients
with CPM presented adequate data to be included in
the meta-analysis (Fig. 1). Of the 24 cohort studies,
six18,34,37,40,44,47 were prospective and the remaining
1811,20,31–33,35,36,38,39,41–43,45,46,48–51 were retrospective
(Table S1, supporting information).
A number of studies presented both an unadjusted and
adjusted HR. As adjustment factors varied widely between
studies (Table S2, supporting information), meta-analysis
was stratified according to whether the HR was unadjusted
or adjusted.
Quality of research
There was a low risk of bias from study participation.
The moderate risk of bias due to study attrition reflects
the poor reporting of loss to follow-up. There was a low
risk of bias due to prognostic factor measurement. Prog-
nostic factors were objective, clearly defined and clinically
relevant. Reporting of all prognostic factors and treat-
ment variations was incomplete in the majority of studies,
resulting in a moderate risk of bias. The presentation
of results and analytical strategy was sufficient in the
majority of studies resulting in a low risk of bias (Table S3,
supporting information).
Pooled median OS across all studies was 32 (range
12⋅2–51) months, with a pooled median follow-up of 28⋅1
(13⋅3–62⋅4) months (Table S4, supporting information).
© 2019 The Authors. www.bjsopen.com BJS Open
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Patient factors
Age
The pooled median age of patients included was 54 (range
45⋅5–69⋅3) years. Eleven studies18,20,33,34,37,40,42,48–50,52
reported on age as a prognostic factor and ten presented
adequate data to be included in the meta-analysis. Five
studies categorized age into binary outcomes that could
not be combined meaningfully. The pooled unadjusted
HR was 1⋅00 (95 per cent c.i. 0⋅98 to 1⋅03) (I2 = 38⋅5 per
cent) and adjusted HR was 1⋅00 (0⋅96 to 1⋅04) (I2 = 69⋅3
per cent), for an increase in age of 1 year (Fig. 2; Fig. S1,
supporting information). These data provide no evidence
that age is a useful predictor of OS.
Sex
Nine studies18,20,34,36,37,40,42,51,52 reported on the effect of
sex onOS and eight presented adequate data to be included
in the meta-analysis. The pooled unadjusted HR for male
sex was 1⋅20 (95 per cent c.i. 0⋅83 to 1⋅71) (I2 = 33⋅8 per
cent) and adjusted HR was 1⋅73 (1⋅20 to 2⋅48) (I2 = 11⋅6
per cent) (Fig. 2; Fig. S1, supporting information). It is
therefore unclear whether sex is a useful predictor of OS.
Eastern Cooperative Oncology Group performance status
Five studies18,31,43,52,53 reported on the influence of East-
ern Cooperative Oncology Group (ECOG) status on OS,
and three presented adequate data to be included in the
meta-analysis. The pooled unadjusted HR for an ECOG
score of at least 2 was 1⋅77 (95 per cent c.i. 0⋅85 to 3⋅67)
(I2 = 0 per cent) (Fig. 2; Fig. S1, supporting information).
These data provide no evidence that ECOG is a useful pre-
dictor of OS.
Tumour factors
Adverse primary tumour features
Three studies18,33,52 reported on the influence of adverse
features of the primary tumour (obstruction or perforation)
on OS; two presented adequate data to be included in
the meta-analysis. The pooled adjusted HR for adverse
features of the primary tumour was 2⋅91 (95 per cent c.i.
1⋅5 to 5⋅64) (I2 = 0 per cent) (Fig. 2; Fig. S1, supporting
information). These data indicate that adverse primary
features are a useful predictor of decreased OS (Table S5,
supporting information).
Rectal or colonic primary
Eight studies20,34,36,40,43,47,53,54 reported on the influence of
a rectal or colonic primary on OS and six presented ade-
quate data to be included in the meta-analysis. The pooled
unadjusted HR for rectal primary (compared with colonic
primary) was 1⋅48 (95 per cent c.i. 0⋅71 to 3⋅09) (I2 = 73⋅8
per cent) (Fig. 2; Fig. S1, supporting information). These
data provide no evidence that a rectal primary is a useful
predictor of OS.
Lymph node metastasis
Eleven studies11,18,33–35,37,48–50,53,54 reported on the effect
of LN status on OS; nine presented adequate data to be
included in the meta-analysis. The pooled unadjusted HR
for positive LNs (compared with negative LNs) was 1⋅42
(95 per cent c.i. 1⋅06 to 1⋅92) (I2 = 0 per cent) and adjusted
HR was 1⋅08 (0⋅60 to 1⋅95) (I2 = 68⋅6 per cent) (Fig. 2;
Fig. S1, supporting information). It is therefore unclear
whether lymph nodes are a useful predictor of OS.
Tumour differentiation
Two studies34,40 reported on the effect of primary tumour
differentiation on OS. The pooled unadjusted HR for
well differentiated tumours was 0⋅90 (95 per cent c.i. 0⋅18
to 4⋅40) (I2 = 72⋅4 per cent) (Fig. 2; Fig. S1, supporting
information). These data provide no evidence that primary
tumour differentiation is a useful predictor of OS.
Timing of colorectal peritoneal metastasis (synchronous or
metachronous)
Three studies11,40,54 reported on the effect of the tim-
ing of CPM (synchronous or metachronous) on OS.
Two presented adequate data to be included in the
meta-analysis. The pooled unadjustedHR for synchronous
CPM was 1⋅13 (95 per cent c.i. 0⋅56 to 2⋅28) (I2 = 57⋅1 per
cent) (Fig. 2; Fig. S1, supporting information), indicating
that the timing of CPM is not a useful predictor of OS.
Ascites
Two studies18,40 reported on the effect of malignant ascites
on OS. One paper40 presented an unadjusted HR (1⋅50, 95
per cent c.i. 0⋅70 to 3⋅21) and one18 an adjusted HR (3⋅23,
1⋅56 to 6⋅69) (Fig. 2; Fig. S1, supporting information), so it
was not possible to provide a pooled effect estimate.
Hepatic metastasis
Eleven studies18,31,34–38,43,44,47,50 reported on the effect of
surgically treated hepatic metastasis on OS. Seven pre-
sented adequate data to be included in the meta-analysis.
The pooled unadjusted HR for surgically treated hepatic
metastasis was 1⋅36 (95 per cent c.i. 0⋅85 to 2⋅16) (I2 = 43⋅6
per cent) and the adjusted HR was 2⋅49 (0⋅74 to 8⋅41)
(I2 = 85⋅3 per cent) (Fig. 2; Fig. S1, supporting informa-
tion). These data provide no evidence that the presence
of surgically treated hepatic metastasis is a useful predictor
of OS.
© 2019 The Authors. www.bjsopen.com BJS Open
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Fig. 2 Effect of prognostic factors on overall survival
Age (2) (3)
Patient factors
Hazard ratio
1·00 (0·95, 1·03)
1·00 (0·96, 1·04)
1·20 (0·83, 1·71)
1·73 (1·20, 2·48)
1·77 (0·85, 3·67)
2·38 (1·17, 4·82)
1·48 (0·71, 3·09)
0·79 (0·43, 1·44)
1·42 (1·06, 1·92)
1·08 (0·60, 1·95)
1·10 (0·70, 1·72)
1·50 (0·70, 3·21)
3·23 (1·56, 6·69)
1·36 (0·85, 2·16)
2·49 (0·74, 8·41)
2·51 (1·03, 6·10)
1·66 (0·68, 4·03)
1·21 (1·06, 1·38)
0·90 (0·43, 1·89)
2·90 (1·95, 4·31)
3·12 (2·02, 4·80)
2·09 (1·04, 4·21)
2·57 (0·68, 9·67)
5·80 (2·80, 12·01)
1·07 (1·02, 1·12)
5·04 (2·74, 9·29)
2·09 (1·39, 3·15)
1·76 (0·61, 5·11)
3·28 (0·77, 13·94)
1·07 (1·04, 1·11)
1·23 (0·78, 1·95)
1·95 (0·33, 11·54)
1·56 (0·74, 3·31)
0·65 (0·39, 1·09)
1·00 (0·63, 1·58)
1·75 (1·18, 2·59)
0·59 (0·41, 0·82)
1·75 (1·18, 2·59)
1·56 (1·14, 2·15)
1·44 (0·58, 3·62)
1·61 (1·31, 1·97)
1·16 (0·99, 1·36)
0·90 (0·18, 4·4)
1·13 (0·56, 2·28)
2·91 (1·50, 5·65)
Tumour factors
PCI score (13) (11)
Treatment factors
CC score (3) (5)
Sex (5) (4)
ECOG performance (2) (1)
Adverse feature (obstruction or perforation) (0) (2)
Rectal or colonic primary (4) (2)
Lymph node metastasis (4) (5)
Tumour differentiation (2) (0)
Synchronous or metachronous PM (2) (0)
Ascites (1) (1)
Hepatic metastasis (4) (3)
Signet ring histology (1) (2)
Mucinous histology (3) (0)
Presence of GI anastamosis (1) (1)
Unadjusted > 20
Unadjusted > 15
Unadjusted > 12
Unadjusted > 10
Unadjusted > 6
Unadjusted per point increase
Adjusted > 20
Adjusted > 15
Adjusted > 10
Adjusted > 6
Adjusted per point increase
Previous surgical score (2) (1)
Postoperative morbidity (2) (1)
Adjuvant chemotherapy (1) (1)
Neoadjuvant chemotherapy (2) (0)
Unadjusted CC0 versus ≥ CC1
Unadjusted CC0/1 versus ≥ CC2
Adjusted CC0 versus ≥ CC1
Adjusted CC0/1 versus ≥ CC2
Adjusted per point > CC
0·01 0·02 0·04 0·08 0·16 0·32
Hazard ratio
0·64 1·28 2·56 5·12 10·24
Adjusted
Unadjusted
Hazard ratios are shown with 95 per cent confidence intervals. Values in parentheses after each factor indicate the numbers of studies providing unadjusted
and adjusted hazard ratios respectively. ECOG, Eastern Cooperative Oncology Group; PM, peritoneal metastasis; GI, gastrointestinal; PCI, Peritoneal
Carcinomatosis Index; CC, completeness of cytoreduction.
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Signet ring histology
Three studies11,42,46 reported on the effect of signet
ring histology on OS. Two included adequate data to
be included in the meta-analysis. The pooled adjusted
HR for signet ring histology was 1⋅65 (95 per cent c.i.
0⋅68 to 4⋅03) (I2 = 0 per cent) (Fig. 2; Fig. S1, supporting
information), suggesting that signet ring histology is not a
useful predictor of OS.
Mucinous histology
Four studies11,43,46,49 reported on the influence of mucin-
ous histology on OS. Three studies presented ade-
quate data to be included in the meta-analysis. The
pooled unadjusted HR for mucinous histology was 1⋅10
(95 per-cent c.i. 0⋅70 to 1⋅72) (I2 = 0 per cent) (Fig. 2; Fig.
S1, supporting information), suggesting that mucinous
histology is not a useful predictor of OS.
Gastrointestinal anastomosis in CRS+HIPEC
Two studies18,43 reported on the effect of one or more gas-
trointestinal anastomoses onOS.One paper43 presented an
unadjusted HR (1⋅21, 95 per cent c.i. 1⋅06 to 1⋅38) and the
other18 an adjusted HR (0⋅90, 0⋅43 to 1⋅89) (Fig. 2; Fig. S1,
supporting information), so it was not possible to provide
a pooled effect estimate.
Peritoneal Carcinomatosis Index
Eighteen studies11,20,31–38,40,41,43,45,49,50,54,55 reported on
the effect of the extent of CPM as described by the PCI;
16 studies presented adequate data to be included in the
meta-analysis. PCI score was reported as a continuous
variable or condensed into categorical variables.
A PCI score greater than the following levels was predict-
ive of reduced OS: PCI above 20 (unadjusted HR 2⋅90, 95
per cent c.i. 1⋅95 to 4⋅31, I2 = 0 per cent; adjustedHR 5⋅04,
2⋅74 to 9⋅29, I2 = 0 per cent); PCI above 15 (unadjusted
HR 3⋅12, 2⋅02 to 4⋅80, I2 = 0 per cent; adjusted HR 2⋅09,
1⋅39 to 3⋅15, I2 = 0 per cent). PCI as a continuous variable
was predictive of reduced OS: pooled unadjusted HR 1⋅07
(1⋅02 to 1⋅12) per increase of one PCI point (I2 = 46⋅1 per
cent); pooled adjustedHR 1⋅07 (1⋅04 to 1⋅11) per PCI point
increase (I2 = 67⋅1 per cent). Lower PCI levels were not
predictive of OS: PCI above 10 (unadjusted pooled HR
2⋅57, 0⋅68 to 9⋅67; I2 = 90 per cent); PCI above 6, adjusted
pooled HR 3⋅28 (0⋅77 to 13⋅94; I2 = 92 per cent) (Fig. 2;
Fig. S1, supporting information).
Treatment factors
Previous surgical score
Three studies11,34,42 reported on the influence of the pre-
vious surgical score (PSS) on OS. The pooled unadjusted
HR for a PSS of at least 2 was 1⋅23 (95 per cent c.i. 0⋅78 to
1⋅95) (I2 = 0 per cent) (Fig. 2; Fig. S1, supporting informa-
tion). These data provide no evidence that PSS is a useful
predictor of OS.
Postoperative morbidity
Three studies40,43,50 reported on the association between
postoperative morbidity and OS. The pooled unadjusted
HR for a Clavien–Dindo complication of grade III or
above was 1⋅56 (95 per cent c.i. 0⋅74 to 3⋅31) (I2 = 48⋅7 per
cent) (Fig. 2; Fig. S1, supporting information). These data
provide no evidence that postoperativemorbidity is a useful
predictor of OS.
Neoadjuvant and adjuvant chemotherapy
Neoadjuvant and adjuvant treatment of the primary
tumour was reported poorly (Table S6, supporting infor-
mation). No study reported response to treatment, or
whether it was completed as planned.
Two studies11,43 reported on the effect of neoadjuvant
chemotherapy before CRS+HIPEC on OS. The pooled
unadjusted HR for the use of neoadjuvant chemotherapy
was 1⋅00 (95 per cent c.i. 0⋅63 to 1⋅58) (I2 = 0 per cent)
(Fig. 2; Fig. S1, supporting information). These data pro-
vide no evidence that neoadjuvant chemotherapy is a useful
predictor of OS.
Adjuvant chemotherapy
Four studies11,35,43,50 reported on the effect of adjuvant
chemotherapy after CRS+HIPEC on OS. The pooled
unadjusted HR for adjuvant chemotherapy was 0⋅60 (95
per cent c.i. 0⋅29 to 1⋅21) (I2 = 68⋅1 per cent) (Fig. 2; Fig.
S1, supporting information), which suggests there is no
evidence that use of adjuvant chemotherapy is predictive
of OS.
Completeness of cytoreduction
Eight studies11,32,35,40,42,43,51,55 reported on the effect of
the completeness of cytoreduction on OS; seven presented
adequate data to be included in the meta-analysis. A CC
score above zero was predictive of a reduction in OS (un-
adjusted HR 1⋅75, 95 per cent c.i. 1⋅18 to 2⋅59) (I2 = 79⋅5
per cent), as was a CC score of 2 or more (HR 1⋅61,
1⋅31 to 1⋅97) (I2 = 0 per cent) (Fig. 2; Fig. S1, supporting
information).
Discussion
This systematic review and meta-analysis examined
the effect of prognostic factors on OS following CRS+
HIPEC for CPM. Emergency presentation with obstruc-
tion or perforation of the primary tumour as well as the
© 2019 The Authors. www.bjsopen.com BJS Open
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extent of CPM and the completeness of resection,
as described by the PCI and the CC score respectively,
were the only significant prognostic factors.
An emergency presentation of the primary tumour with
obstruction or perforation was predictive of reduced OS
(for both synchronous and metachronous CPM). A num-
ber of factors may contribute to this. In the primary setting,
colorectal cancers presenting with obstruction or perfor-
ation are associated with decreased cancer-specific sur-
vival and increased postoperative mortality56. Obstructed
or perforated colorectal cancer is, by definition, advanced
in stage and increases the risk of metastasis; additionally,
emergency presentation limits the possibility of neoadju-
vant treatment and may delay adjuvant treatment owing to
postoperative morbidity. The extent of peritoneal metas-
tasis as described by the PCI was predictive of reduced
OS as a continuous variable and when the PCI score was
12 or above. A complete cytoreduction (CC0) was pre-
dictive of improved OS. Improving patient selection is
therefore reliant on the ability to predict accurately the
extent of peritoneal metastasis and the ability to resect it
completely. Specialist radiologists have demonstrated good
concordance between radiological and surgical PCI esti-
mations, particularly when combiningmodalities; however,
these tend to be most accurate in patients with high PCI
scores57,58. In some centres this is used in combination with
diagnostic laparoscopy before CRS+HIPEC. This is feas-
ible in the majority of patients and may help to reduce the
laparotomy rate in patients for whom CRS+HIPEC may
not be possible59.
Included patients were relatively young at 54 (range
45–69) years compared with the incident age of colorectal
cancer (80–90 years)60 In addition, performance status was
not reported by the majority of studies in the review, and
limited to an ECOG score of less than 2 by a further nine.
Within these limits, no other patient or tumour factor was
predictive of OS.
Details of neoadjuvant and adjuvant treatments were
reported poorly in the included studies. Within these
limits, the use of neoadjuvant or adjuvant chemother-
apy was not predictive of OS after CRS+HIPEC. One
meta-analysis, by Kwakman and colleagues61 from 2016,
examined the effect of clinicopathological variables only
on OS following CRS+HIPEC. Significant prognostic
factors identified in the present review (adverse features of
the primary tumour, PCI, CC score) were not comparable
with those from Kwakman et al.61 as they were not exam-
ined. In contrast to the present study, Kwakman and
co-workers61 found performance status, the presence of
lymph node or hepatic metastasis, tumour differentiation,
signet ring histology, a rectal primary and the use of
neoadjuvant chemotherapy to be predictive prognostic
factors. A number of differences may explain this vari-
ation in findings: the exclusion of 73 papers described as
unavailable in full text may introduce a potential selec-
tion bias61. In addition, a number of studies included by
Kwakman and colleagues were excluded in the present
study for the following reasons: presentation of inadequate
data to estimate the HR accurately13,52,54,62 the inclusion
of mixed primary tumours48,63,64, and the inclusion of
patients having repeat CRS+HIPEC procedures. Finally,
the meta-analysis61 combined all studies regardless of the
presentation of unadjusted or adjusted HR.
The strengths of the present study include the compre-
hensive and systematic literature search including 3128
patients with CPM undergoing CRS+HIPEC, all poten-
tial prognostic factors were included, and a consistent asso-
ciation was found between predictive prognostic factors
across different studies. The low heterogeneity associated
with these factors adds to the strength and generalizabil-
ity of the findings. The application of strict inclusion cri-
teria limits the potential impact of factors such as mixed
primary tumour origin. The present analysis takes into
account the adjustment factors used in primary studies to
ensure meta-analysis of time to event data was performed
only when data were comparable.
A number of limitations must, however, be acknow-
ledged. This review is limited by the quality of primary
studies and the heterogeneity of the population. Prognos-
tic factor systematic reviews, by their nature, represent one
of the most difficult categories due to their retrospective
and observational nature. As CRS+HIPEC is performed
at tertiary centres, data concerning the primary tumour
and its treatment may not have been captured or reported
fully. Additionally, the statistical analysis and presentation
of data necessary for accurate meta-analysis varied widely
across primary studies, which may introduce a degree of
inclusion bias.
There was a lack of molecular and genetic data concern-
ing patients with CPMundergoing CRS+HIPEC in com-
parison with studies of primary colorectal cancer, and this is
an area for future research. Discordance between primary
genetic mutations and those in peritoneal metastases may
identify novel therapeutic targets and prognostic markers
in this metastatic group. Recent research by Schneider and
colleagues65 found that RAS/RAF mutations impair sur-
vival after CRS/HIPEC, although this is the only study
that has considered this prognostic factor and validation is
required. Further large-scale research is needed to account
for these factors; this would require collaboration between
CRS+HIPEC centres, standardization of the analysis and
presentation of prognostic factor time to event data.
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